Follow us on...

Search News Archives
«  »

The European Biopolymer Summit

MediSens Conference 2018

3rd International Conference on Enzymology & Molecular Biology

Forensics Europe Expo

The European Drug Safety Summit 2018


Media Partners



Subscibe to our YouTube channel



E-Newsletter Month  
Lab Bulletin Monthly Update December view archive
Microscopy & Image Analysis December view archive
Separation Science December view archive
Weekly Update January (3) view archive

For further information or to sign up to receive any of our E-Newsletters click here

NovAliX Turns to High-Resolution Cryo-Transmission Electron Microscopy for Pre-Clinical Drug Discovery Research

publication date: Mar 22, 2017
author/source: Thermo Fisher Scientific

Thermo Fisher Scientific’s Cryo-TEM provides critical information for small molecule and biologic drug discovery 

thermo fisher scientificA new contract research laboratory operated by France-based NovAliX will provide pharmaceutical companies with access to high-resolution cryo-transmission electron microscopy (cryo-TEM) by Thermo Fisher Scientific for facilitating small molecule and biologic drug discovery. NovAliX’s new laboratory will use the cryo-TEM to provide two-dimensional (2D) and three-dimensional (3D) characterization of small molecule and biological samples. NovAliX has completed its first program with a Japanese pharmaceutical customer. It has multiple projects planned with additional customers, including some of the top pharmaceutical companies.

“Cryo-TEM has great potential in drug discovery applications; it is highly complementary to traditional methods, such as x-ray crystallography and nuclear magnetic resonance,” said Denis Zeyer, CEO, NovAliX. “For small molecules research, cryo-TEM provides structural information about multi-protein complexes or membrane proteins. For biologics, cryo-TEM can deliver critical information about antibody selection, epitope mapping and formulation. This information helps the drug discovery process to become more consistent and reproducible, which may ultimately result in better therapeutic candidates.”

“As pharmaceutical companies continue to accelerate drug discovery, cryo-TEM can play a key role across many aspects of this process,” said Peter Fruhstorfer, vice president and general manager, Life Sciences, Materials and Structural Analysis, Thermo Fisher. “Cryo-TEM helps researchers examine a broader range of biological structures, and provides the ability to visualize complicated biologics.”

NovAliX’s new laboratory also includes x-ray diffraction (XRD), nuclear magnetic resonance (NMR), micro-array surface plasmon resonance (SPR) and other technologies. The addition of cryo-TEM enables NovAliX to resolve features in biological molecules as small as a few Ångstroms (roughly a few atoms), sufficient to reveal tertiary and quaternary protein structure and, in some cases, to identify individual amino acid side chains. It can look at molecules and molecular complexes of any size, without crystallization. Equally important, cryo-TEM samples, which are frozen in vitreous (non-crystalline) ice, can be examined in a near-native, fully-hydrated state. Cryo-TEM has proven to be complementary to NMR and XRD as researchers have used computational techniques to fit their atomic-scale information into cryo-TEM 3D models.

more about thermo scientific

more news from thermo scientific


Can't find what you are looking for?

Search by company, product or location

Company Name:



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have a product enquiry, please contact the supplier directly.

Lab Bulletin is published by newleaf marketing communications ltd